Scholars@Duke
Brian James Caveney

Brian James Caveney

Medical Assistant Professor in the Department of Family Medicine and Community Health
Family Medicine and Community Health, Occupational & Environmental
brian.caveney@duke.edu
Duke Box 3834, Durham, NC 27710
2200 W Main St, Durham, NC 27710

Selected Publications

Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage.

Journal Article Mol Diagn Ther · September 2025 BACKGROUND: Molecular profiling is quickly becoming standard for patients with advanced cancer, with an increasing number of biomarker-directed therapies and innovative precision diagnostics available. However, with the expansion of relevant biomarkers, cl ... Full text Link to item Cite

RB1 expression and HR proficiency define a poor prognosis subtype of high grade serous ovarian cancer.

Journal Article Sci Rep · August 12, 2025 High-grade serous ovarian carcinoma (HGSOC) is a molecularly heterogeneous and lethal malignancy, with late-stage diagnosis contributing to high risk of recurrence and poor clinical outcomes. Although homologous recombination (HR) deficiency and retinoblas ... Full text Link to item Cite

Abstract P3-01-24: Triple negative and non-triple negative breast cancer have distinct metabolic characteristics associated with divergent survival outcomes

Conference Clinical Cancer Research · June 13, 2025 AbstractIntroduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with high histologic grade and poor prognosis. TNBC is also known to be associated with modified m ... Full text Cite

Abstract 3401: Pharmacogenomic landscape of UGT1A1 in cancer patients from the Avera Sequencing and Analytics Protocol (ASAP) registry

Conference Cancer Research · April 21, 2025 AbstractPurpose:Pharmacogenomic (PGx) testing enables clinicians to identify patients at increased risk of adverse events after chemot ... Full text Cite

Analytical Validation of the Labcorp Plasma Complete Test, a Cell-Free DNA Comprehensive Genomic Profiling Tool for Precision Oncology.

Journal Article J Mol Diagn · March 2025 To help guide treatment decisions and trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations circulating in the blood. Labcorp Pl ... Full text Link to item Cite

Analysis of real world FRĪ± testing in ovarian, fallopian tube, and primary peritoneal cancers.

Journal Article Gynecol Oncol · January 2025 BACKGROUND: Epithelial ovarian cancer (EOC) remains a significant challenge in gynecologic oncology, particularly in the context of platinum-resistant disease. Mirvetuximab soravtansine (MIRV), was approved after trials revealed favorable response and surv ... Full text Link to item Cite

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.

Journal Article Front Oncol · 2025 The growing importance of HER2 expression as a biomarker across multiple cancers is largely driven by advances in HER2-directed antibody-drug conjugates. The recent approval of trastuzumab deruxtecan (T-DXd) as a tumor-agnostic therapy has revolutionized t ... Full text Link to item Cite

RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting

Journal Article Frontiers in Genetics · January 1, 2025 Introduction: NTRK1, NTRK2, and NTRK3 gene fusions are rare oncogenic driver alterations found in diverse tumor types of adults and children. They are clinically important biomarkers as tumors harboring these genomic alterations have high response rates to ... Full text Cite

Empowering patients for biomarker-informed care: digital education to bridge HER2-low knowledge gaps in metastatic breast cancer.

Journal Article Front Digit Health · 2025 BACKGROUND: The emergence of trastuzumab deruxtecan has led to significant improvement in clinical outcomes for patients with HER2-low metastatic breast cancer, which accounts for approximately half (45%-55%) of breast cancer diagnoses. However, little is ... Full text Link to item Cite

Abstract B028: Analytical validation of tumor-informed whole genome sequencing analyses for detection of molecular residual disease in solid tumors

Conference Clinical Cancer Research · November 13, 2024 AbstractIntroduction: Across all patients diagnosed with solid tumors, approximately two-thirds initially present with locoregional disease and are potentially eligible for curative-intent intervention. Howe ... Full text Cite

A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors.

Journal Article Brief Bioinform · September 23, 2024 Disparities in cancer diagnosis, treatment, and outcomes based on self-identified race and ethnicity (SIRE) are well documented, yet these variables have historically been excluded from clinical research. Without SIRE, genetic ancestry can be inferred usin ... Full text Link to item Cite

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.

Journal Article Oncol Ther · June 2024 INTRODUCTION: Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated biomarkers ... Full text Link to item Cite

Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.

Conference Journal of Clinical Oncology · June 1, 2024 1096Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment triple negative breast cancer (TNBC). However, not all patients with TNBC benefit from the addition of ICIs due to factors such as intrinsic and acquired resistance to IC ... Full text Cite

Analytical validation of the Labcorp Plasma Complete test to enable precision oncology through solid tumor liquid biopsy comprehensive genomic profiling.

Conference Journal of Clinical Oncology · June 1, 2024 3063Background: To help guide treatment decisions and enable clinical trial matching for cancer patients, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy may be used as a complementary approach to assess tumor-specific DNA al ... Full text Cite

Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

Journal Article J Pers Med · April 30, 2024 Background: KEYNOTE-522 resulted in FDA approval of the immune checkpoint inhibitor pembrolizumab in combination with neoadjuvant chemotherapy for patients with early-stage, high-risk, triple-negative breast cancer (TNBC). Unfortunately, pembrolizumab is a ... Full text Link to item Cite

Abstract 5020: Pre-analytical characterization of cell-free DNA to enable liquid biopsy for solid tumors

Conference Cancer Research · March 22, 2024 AbstractBackground: The integration of liquid biopsy in oncology has transformed clinical management of patients with cancer. Cell-free DNA (cfDNA) represents extracellular nucleic acid fragments shed during ... Full text Cite

Abstract 5017: Analytical performance of contrived samples for validation of liquid biopsy assays

Conference Cancer Research · March 22, 2024 AbstractIntroduction: Cell-free DNA (cfDNA) extracted from plasma is critical for the analytical validation of liquid biopsy assays. cfDNA is comprised of genetic material from tumor and non-tumor cells, whi ... Full text Cite

Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.

Journal Article J Transl Med · February 7, 2024 BACKGROUND: Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression drives the metastasis and progression of lung cancer, and is associated with poor pro ... Full text Link to item Cite

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.

Journal Article Front Immunol · 2024 INTRODUCTION: Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and enriched targetable genomic alterations compared to older patients. However, previo ... Full text Link to item Cite

Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Immune checkpoint inhibitors (ICIs) are a therapeutic option for patients with triple-negative breast cancer (TNBC), however resistance and non-response remain an unmet clinical need. Human leukocyte antigens (HLAs) play an important role in in ... Full text Cite

A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability

Conference Journal of Clinical Oncology · January 1, 2024 Background: Microsatellite instability (MSI) occurs via defects in mismatch repair (MMR) and is characterized by high tumor mutational burden (TMB) and a robust inflammatory response. Accurate MSI-high classification of immune-evasive tumors is vital due t ... Full text Cite

Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.

Journal Article Breast Cancer (Dove Med Press) · 2024 BACKGROUND: The understanding of molecular characteristics of HER2-low breast cancer is evolving since the establishment of trastuzumab deruxtecan. Here, we explore the differences in expression patterns of immune-related genes in the tumor immune microenv ... Full text Link to item Cite

Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer-a case series of divergent results from a large reference laboratory.

Journal Article Front Oncol · 2024 Clinical management of non-small cell lung cancer (NSCLC) requires accurate identification of tumor-specific genetic alterations to inform treatment options. Historically, providers have relied on single-gene testing (SGT) for actionable variants due to a ... Full text Link to item Cite

Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Journal Article Frontiers in Oncology · January 1, 2024 Introduction: Matching patients to an effective targeted therapy or immunotherapy is a challenge for advanced and metastatic non-small cell lung cancer (NSCLC), especially when relying on assays that test one marker at a time. Unlike traditional single mar ... Full text Cite

Real-World studies in diabetes needed to improve medication adherence and persistence

Journal Article American Health and Drug Benefits · June 1, 2017 Cite

Pay-for-Performance Incentives: Holy Grail or Sippy Cup?

Journal Article N C Med J · 2016 The health care system is slowly evolving from fee-for-service care to other forms of payment. Pay-for-performance contracts based on quality, patient satisfaction, and utilization are an important development along the continuum. The metrics are not perfe ... Full text Link to item Cite

Pharmaceutical interventions for obesity: a public health perspective.

Journal Article Diabetes Obes Metab · June 2011 The prevalence of obesity, a major risk factor for many chronic diseases, has risen in most developed countries over the past several decades. The economic burden for both public and private health care systems is substantial. Although certain non-pharmace ... Full text Link to item Cite

Implications of patient selection and surgical technique for primary total knee arthroplasty.

Journal Article W V Med J · 1996 Between 1983 and 1992, one surgeon at Wheeling Hospital in Wheeling, W.Va., performed 121 primary cruciate-sparing total knee arthroplasties on patients with degenerative joint disease. Rigorous preoperative screening criteria and surgical protocol were de ... Link to item Cite

Lessons from the Swedish health care system.

Journal Article W V Med J · September 1994 Link to item Cite

It's time for tort reform!

Journal Article W V Med J · May 1994 Link to item Cite

A teenager looks at malpractice.

Journal Article Ala Med · July 1991 Link to item Cite

The medical dichotomy: malpractice.

Journal Article W V Med J · April 1991 Link to item Cite